Mcmaster Childrens Hospital

HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations. Importantly, Exerkine’s R&D pipeline is maturing and generating patented nutrition-based therapies that are supported by strong clinical results. These therapies are particularly impactful at a time when North American obesity rates and age-related disorders are at pandemic levels. The biggest threats to North American health are obesity and age-related disorders (i.e. muscle loss, cardiovascular disease, type 2 diabetes, dementia). Current nutritional strategies to combat these health issues have been shown to be ineffective in the long term. Exerkine is poised to change this paradigm through proprietary products that are built and backed by science. Founded by Dr. Mark Tarnopolsky, and in partnership with McMaster University, Exerkine is a Canadian nutritional supplements company built upon decades of research. Utilizing advances in mitochondrial sciences, exercise physiology, and nutrition, Exerkine leverages pharmaceutical-industry R&D standards to create novel nutrition-based products. This rigorous development pipeline sets Exerkine apart by ensuring that its nutritional products are supported by high quality preclinical and clinical research, supported by proven health claims, and meet safety and regulatory standards, which, when combined, deliver superior products to consumers. Exerkine is led by internationally renowned physician-scientist, Dr. Mark Tarnopolsky, PhD, MD, FRCP(C). As the founder, CEO and CSO of Exerkine, Dr. Tarnopolsky is applying his clinical and scientific expertise to lead Exerkine’s commercial and research development. Having successfully co-founded and acted as CSO for Life Science Nutritionals, he has expanded his business acumen as the co-founder and Vice President of Business Development for Systemic Therapeutics, and CSO for SoftTabs. Additionally, he has forged a career studying the impact of exercise and nutritional therapies in the treatment of aging-acquired and genetic disorders. He holds an endowed chair in, and is division head of, Neuromuscular and Neurometabolic Diseases Clinic at the McMaster University Children’s Hospital and is an advisor on numerous medical advisory boards. Dr. Tarnopolsky’s extensive research and medical knowledge is exemplified by over 500 published scientific and medical manuscripts (h index = 141) and has received high-profile attention from media outlets such as CBC News, ABC News, Wall Street Journal, New York Times, and Time magazine. “Exerkine is at the forefront of a new phase in its development. Having been supported by McMaster University as a start-up company, we are looking to expand our operations by fostering new partnerships, expanding our research program, and by bring our game-changing evidence-backed products to market.” Dr. Tarnopolsky continued to say “we are thrilled to see what the future holds for Exerkine - a company that’s truly built and backed by science.” Core to its R&D strategy, Exerkine is actively engaged in developing a diverse patent portfolio. The corporation’s initial filing outlined the novel use of interleukin-15, a cytokine known to be involved in a variety of biological pathways, to promote mitochondrial biogenesis and drive improvements in skin health. This patent has been awarded in both Canada (CA2917944C) and the United States (US10064919B2) and has garnered attention from companies in the skincare and beauty industry. Exerkine has since gone on to develop and submit over two dozen patent applications and the company will be making several exciting announcements as its portfolio matures. As part of its evolving commercial strategy, Exerkine launched its nutrition subdivision, StayAbove Nutrition. Through StayAbove Nutrition, Exerkine is marketing several novel nutrition-based products to the consumer. These products are designed to target a health disorder from multiple pathways to yield a combined therapeutic benefit. Clinical results have shown that these products not only provide preventative options to combat obesity and aging-related disorders, but also show treatment options for those already suffering from these conditions. Exerkine is excited to present its two flagship products: Muscle 5 (Muscle Enhancement Supplement) and Trim 7 (Weight Management Supplement) under StayAbove Nutrition. Muscle 5 is a nutritional supplement containing 5 carefully selected ingredients shown to enhance muscle mass and strength in younger and older adults. Unlike single ingredient protein powders, Muscle 5’s patented design is proven to build muscle and strength, and has been shown to impact blood cholesterol levels, as well as cognition (Nilsson et al, 2020; Bell et al, 2017; Bell et al, 2019). Trim 7 is a weight management supplement containing 7 specific ingredients shown to reduce fat mass but preserve lean mass. Trim7’s patented design focuses on the mitochondria, the cell’s powerhouse, to drive weight loss by turning on the body’s natural fat burning pathways. A significant amount of research and development has already been done on this product, including pre-clinical (Nederveen et al, 2021) work, and the company will be announcing its clinical trial results in a press release shortly. About ExerkineExerkine Corporation is a nutra-pharmaceutical company that is developing a new class of therapies to treat obesity and age-related disorders . Advances in mitochondrial sciences, cell metabolism, exercise physiology and nutrition are fueling innovation in nutrition-based therapies. Exerkine is seeking opportunities to expand its commercial operations, leverage its IP portfolio, and raise capital investment. Additionally, Exerkine provides R&D and consultation services to the nutritional and pharmaceutical industries. Contact us if you wish to learn more and how Exerkine can support your business. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28b3b26b-4cb8-4c38-a7c7-a493359842bd

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development (R&D) Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET. The R&D Day will feature presentations from the Company’s management team and Sheila Singh, M.D., Ph.D., Professor of Surgery and Biochemistry, Chief Pediatric Neurosurgeon at McMaster Children’s Hospital, the Division Head of Neurosurgery at Hamilton Health Sciences, and the inaugural Director of McMaster's new Cancer Research Centre. The event will focus on the Company’s next-generation iPSC-based cell therapy platform technologies and includes a discussion on its strategy in GBM with CNTY-103. For additional information on how to access the event, please visit the Events & Presentations section of Century’s website. About Century TherapeuticsCentury Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com. Century Therapeutics Forward-Looking StatementThis press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. For More Information: Company: Elizabeth Krutoholow – investor.relations@centurytx.comInvestors: Melissa Forst/Maghan Meyers – century@argotpartners.comMedia: Joshua R. Mansbach – century@argotpartners.com

TORONTO, May 31, 2021 (GLOBE NEWSWIRE) -- May 31 marks the end of Brain Cancer Awareness Month. On this day, Brain Cancer Canada turns awareness into action by emphatically supporting groundbreaking research into brain cancer treatment. The charity has made $100,000 available to Dr. Sheila Singh and her research group at McMaster University to target recurrent Glioblastomas (GBMs) with generous support from sponsors, including Scotia Wealth Management, Yamana Gold, and Hampton Securities. Dr. Singh and her team focus on stem-like cells driving recurrent GBMs' functionality, using CRISPR technology to identify a series of essential genes in cancer cells as potential points-of-attack. Specially targeting antibodies or immunotherapies could then disable the function of those genes, potentially offering a new method to treating recurrent GBMs. "Brain Cancer Canada is stepping up to fund research that is in an uncertain but promising stage," said Dr. Sheila Singh, Pediatric Neurosurgeon at McMaster Children's Hospital and Professor of Surgery and Scientist at McMaster University's Michael G. DeGroote School of Medicine. "Early-stage research is harder to get funded but is so essential to make a difference. The funding we are receiving today allows us to explore and solidify hopeful indications that there might be a viable therapy in our approach". GBMs are the most aggressive and common primary brain cancers. The outcomes for patients are devastating. Most patients undergo surgical removal, radiation and chemotherapy, which can significantly affect their quality of life. On average, GBMs regrow seven to nine months after diagnosis. Most patients do not survive beyond fifteen months after diagnosis. The five-year survival rate is only between 5.5-6.8%. Recurrent GBMs are significantly different from patients' original GBMs. They respond substantially less to treatment, causing them to be fatal. Successfully targeting the unique makeup of these recurrent GBMs could potentially mean a breakthrough. "Our charity focuses on supporting the fight against brain cancers by funding research, treatment and technology," said Brain Cancer Canada Chair Angela Scalisi. "I am grateful to the generous donors that contributed to this research. We were able to put their donations to use on the day we closed Brain Cancer Awareness Month. That is an impressive result for an organization without any paid employment. It shows that we can quickly deliver as much of our funds where they belong, thanks to the bold efforts of our Volunteers, Ambassadors and Board Members." "It has been over fifteen years since we have seen a breakthrough in treating brain cancers," said Marc Peeters, Director Partnerships and Stakeholders at Brain Cancer Canada. "Dr. Singh and her team at Sheila Singh Lab are taking an innovative, multidisciplinary approach to unlock new possibilities that are so needed. By supporting their work, we believe we can work step-by-step towards the next critical discovery that could help end this fight in favour of brain cancer patients. This is just a first step in our journey with Sheila Singh Labs and McMaster University, and we look forward to supporting more projects in the future". CONTACT INFORMATION For inquiries, please contact: Marc Peeters, Director Partnerships and Stakeholders at Brain Cancer Canada, marc@braincancercanada.ca, 416 918 6678